VC: Vitae leads with $15M



Vitae leads with $15 million.

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Vitae Pharmaceuticals
Fort Washington, PA

$15 million
NA

GlaxoSmithKline

Much of the money will be used to accelerate its multiple programs into the clinic.

Primera Biosystems
Providence, RI

$11 million
first round

MPM Capital, Burrill and Company

The financing will enable Primera to develop both instrument systems and disease specific diagnostic reagent kits for commercialization.

Panacea Pharmaceuticals
Gaithersburg, MD

$7 million
third round

Mitsubishi Corporation Life Sciences Venture

Proceeds from the offering will be used to move potential products within the company's HAAH Oncology Program towards clinical-stage development.

Pepscan Systems
The Netherlands

$6 million
first round

PPM Oost NV

The funds will be used primarily to further expand Pepscan's portfolio of therapeutic vaccines programs in oncology.

Suggested Articles

Sarepta will negotiate a warning for golodirsen rather than carry out more studies. But the implications of the rejection range beyond golodirsen.

The Pfizer Foundation has awarded 20 grants to organizations involved in tackling infectious diseases in low- and middle-income countries.

The engineered stain of E. coli performed no better than placebo, leading Synlogic to conclude its money is better spent on other assets.